KRAS and non-small cell lung carcinoma: Recently, a promising new drug called Sotorasib (AMG 510), which is a novel KRAS inhibitor targeting the KRAS G12C mutation, was approved for treating patients with metastatic non-small-cell lung cancer harboring the KRAS G12C mutation [8].